PTCT PTC THERAPEUTICS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1070081 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-35.1%
TTM net income YoY-114.1%
TTM EPS YoY-115.5%
Revenue 3-yr CAGR13.1%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin12.8%
Net margin-9.2%
FCF margin0.2%
EBITDA margin18.1%
Returns
ROE—
ROA-3.6%
ROIC (approx.)—
Asset turnover0.39x
Leverage & solvency
Liabilities / assets106.0%
Debt / equity—
Current ratio3.27x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.10x
Accruals ratio-4.0%
Payout ratio—
Capex / revenue0.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $1.73B | $806.78M |
| R&D expense | $455.25M | $534.48M |
| SG&A expense | $347.14M | $300.91M |
| Operating income | $866.93M | -$302.57M |
| Pretax income | $696.62M | -$363.12M |
| Income tax | $13.97M | $176,000 |
| Net income | $682.64M | -$363.30M |
| EBITDA | $905.75M | -$226.91M |
| EPS (basic) | 8.58 | -4.73 |
| EPS (diluted) | 7.78 | -4.73 |
| Weighted avg. shares (diluted) | 88.31M | 76.85M |
| Balance sheet | ||
| Cash & equivalents | $984.65M | $795.32M |
| Short-term investments | $960.72M | $359.99M |
| Receivables | $181.62M | $158.55M |
| Inventory | $79.65M | $23.19M |
| Current assets | $2.27B | $1.37B |
| PP&E, net | $55.37M | $60.97M |
| Goodwill | $82.34M | $82.34M |
| Intangibles | $388.75M | $118.79M |
| Total assets | $2.90B | $1.71B |
| Current liabilities | $968.43M | $580.98M |
| Short-term debt | $286.63M | — |
| Long-term debt | — | $285.41M |
| Total debt | — | $285.41M |
| Total liabilities | $3.10B | $2.80B |
| Shareholders' equity | -$205.31M | -$1.10B |
| Net debt | — | -$509.90M |
| Shares outstanding | 81.47M | 77.70M |
| Cash flow statement | ||
| Operating cash flow | $711.20M | -$107.69M |
| Capital expenditure | $8.86M | $6.50M |
| Free cash flow | $702.34M | -$114.19M |
| Investing cash flow | -$861.98M | $44.18M |
| Financing cash flow | $331.09M | $255.87M |
| Depreciation & amortization | $38.81M | $75.66M |
| Stock-based compensation | $74.55M | $74.61M |
Free plan shows the latest 2 periods; Pro shows all 15 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.